Keros Therapeutics/$KROS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Ticker
$KROS
Sector
Primary listing
Employees
148
Headquarters
Website
KROS Metrics
BasicAdvanced
$464M
32.70
$0.47
1.07
-
Price and volume
Market cap
$464M
Beta
1.07
52-week high
$67.89
52-week low
$9.12
Average daily volume
885K
Financial strength
Current ratio
21.114
Quick ratio
20.398
Long term debt to equity
2.225
Total debt to equity
2.54
Profitability
EBITDA (TTM)
1.672
Gross margin (TTM)
94.23%
Net profit margin (TTM)
8.06%
Operating margin (TTM)
0.13%
Effective tax rate (TTM)
30.20%
Revenue per employee (TTM)
$1,570,000
Management effectiveness
Return on assets (TTM)
0.03%
Return on equity (TTM)
3.33%
Valuation
Price to earnings (TTM)
32.704
Price to revenue (TTM)
2.6
Price to book
0.87
Price to tangible book (TTM)
0.87
Price to free cash flow (TTM)
11.407
Free cash flow yield (TTM)
8.77%
Free cash flow per share (TTM)
1.334
Growth
Revenue change (TTM)
85,820.30%
Earnings per share change (TTM)
-109.11%
3-year revenue growth (CAGR)
126.64%
3-year earnings per share growth (CAGR)
-48.05%
What the Analysts think about KROS
Analyst ratings (Buy, Hold, Sell) for Keros Therapeutics stock.
Bulls say / Bears say
First patient dosed in the Phase 3 RENEW trial of elritercept triggered a $10 million milestone payment under the Takeda license, validating partnership progress and funding execution (GlobeNewswire)
Board’s ongoing strategic review to evaluate alternatives introduces potential management distraction and uncertainty that could delay pipeline advancement (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
KROS Financial Performance
Revenues and expenses
KROS Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Keros Therapeutics stock?
Keros Therapeutics (KROS) has a market cap of $464M as of November 04, 2025.
What is the P/E ratio for Keros Therapeutics stock?
The price to earnings (P/E) ratio for Keros Therapeutics (KROS) stock is 32.7 as of November 04, 2025.
Does Keros Therapeutics stock pay dividends?
No, Keros Therapeutics (KROS) stock does not pay dividends to its shareholders as of November 04, 2025.
When is the next Keros Therapeutics dividend payment date?
Keros Therapeutics (KROS) stock does not pay dividends to its shareholders.
What is the beta indicator for Keros Therapeutics?
Keros Therapeutics (KROS) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.